171 related articles for article (PubMed ID: 21208246)
1. Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics.
Lee HW; Lim MS; Lee J; Jegal MY; Kim DW; Lee WK; Jang IJ; Shin JG; Yoon YR
J Clin Pharm Ther; 2012 Feb; 37(1):105-11. PubMed ID: 21208246
[TBL] [Abstract][Full Text] [Related]
2. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.
Suzuki K; Yanagawa T; Shibasaki T; Kaniwa N; Hasegawa R; Tohkin M
Diabetes Res Clin Pract; 2006 May; 72(2):148-54. PubMed ID: 16325295
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.
Yoo HD; Kim MS; Cho HY; Lee YB
Eur J Clin Pharmacol; 2011 Sep; 67(9):889-98. PubMed ID: 21476064
[TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.
Dai DP; Wang SH; Geng PW; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2014 Apr; 114(4):305-10. PubMed ID: 24118918
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms.
Wang R; Chen K; Wen SY; Li J; Wang SQ
Clin Pharmacol Ther; 2005 Jul; 78(1):90-2. PubMed ID: 16003298
[No Abstract] [Full Text] [Related]
7. Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.
Bae JW; Choi CI; Kim MJ; Oh DH; Keum SK; Park JI; Kim BH; Bang HK; Oh SG; Kang BS; Park HJ; Kim HD; Ha JH; Shin HJ; Kim YH; Na HS; Chung MW; Jang CG; Lee SY
Acta Pharmacol Sin; 2011 Oct; 32(10):1303-8. PubMed ID: 21841812
[TBL] [Abstract][Full Text] [Related]
8. Allele and genotype frequencies of CYP2C9 in a Korean population.
Bae JW; Kim HK; Kim JH; Yang SI; Kim MJ; Jang CG; Park YS; Lee SY
Br J Clin Pharmacol; 2005 Oct; 60(4):418-22. PubMed ID: 16187974
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
10. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
11. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
[TBL] [Abstract][Full Text] [Related]
12. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
[TBL] [Abstract][Full Text] [Related]
13. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
Zhang YF; Chen XY; Guo YJ; Si DY; Zhou H; Zhong DF
Yao Xue Xue Bao; 2005 Sep; 40(9):796-9. PubMed ID: 16342679
[TBL] [Abstract][Full Text] [Related]
14. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
Yin OQ; Tomlinson B; Chow MS
Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
17. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
Choi CI; Kim MJ; Jang CG; Park YS; Bae JW; Lee SY
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):476-80. PubMed ID: 21726410
[TBL] [Abstract][Full Text] [Related]
18. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population.
Lee SS; Kim KM; Thi-Le H; Yea SS; Cha IJ; Shin JG
Ther Drug Monit; 2005 Apr; 27(2):208-10. PubMed ID: 15795654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
